Analysts Issue Forecasts for Intercept Pharmaceuticals Inc’s Q1 2020 Earnings (ICPT)

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) – Analysts at Wedbush issued their Q1 2020 earnings estimates for Intercept Pharmaceuticals in a research note issued on Monday, May 13th. Wedbush analyst L. Moussatos forecasts that the biopharmaceutical company will post earnings of ($2.26) per share for the quarter. Wedbush has a “Outperform” rating and a $243.00 price objective on the stock. Wedbush also issued estimates for Intercept Pharmaceuticals’ Q2 2020 earnings at ($1.97) EPS and Q3 2020 earnings at ($1.63) EPS.

Several other brokerages also recently commented on ICPT. Raymond James reissued a “buy” rating on shares of Intercept Pharmaceuticals in a research note on Thursday, February 14th. Credit Suisse Group reissued an “outperform” rating on shares of Intercept Pharmaceuticals in a research note on Tuesday, February 12th. Needham & Company LLC raised shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a research note on Thursday, January 24th. BidaskClub downgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 23rd. Finally, B. Riley reissued a “buy” rating and issued a $169.00 price objective (up previously from $155.00) on shares of Intercept Pharmaceuticals in a research note on Thursday, February 28th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seventeen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $145.67.

Shares of NASDAQ:ICPT opened at $86.42 on Thursday. The company has a market capitalization of $2.57 billion, a P/E ratio of -7.96 and a beta of 1.49. The company has a quick ratio of 3.72, a current ratio of 3.72 and a debt-to-equity ratio of 19.41. Intercept Pharmaceuticals has a one year low of $65.63 and a one year high of $133.74.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($3.03) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.57) by ($0.46). The company had revenue of $52.25 million during the quarter, compared to the consensus estimate of $52.15 million. Intercept Pharmaceuticals had a negative net margin of 162.49% and a negative return on equity of 617.23%. Intercept Pharmaceuticals’s revenue for the quarter was up 45.3% on a year-over-year basis. During the same period in the previous year, the company earned ($3.22) EPS.

In other Intercept Pharmaceuticals news, EVP Christian Weyer sold 333 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $103.16, for a total value of $34,352.28. Following the completion of the transaction, the executive vice president now directly owns 19,440 shares in the company, valued at approximately $2,005,430.40. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Srinivas Akkaraju sold 23,438 shares of the stock in a transaction on Tuesday, February 19th. The stock was sold at an average price of $128.78, for a total transaction of $3,018,345.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 32,504 shares of company stock valued at $3,919,487. Corporate insiders own 4.90% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of ICPT. Bank of New York Mellon Corp increased its position in shares of Intercept Pharmaceuticals by 3.7% during the third quarter. Bank of New York Mellon Corp now owns 93,227 shares of the biopharmaceutical company’s stock worth $11,780,000 after buying an additional 3,342 shares during the period. Teachers Advisors LLC increased its position in shares of Intercept Pharmaceuticals by 3.0% during the third quarter. Teachers Advisors LLC now owns 43,018 shares of the biopharmaceutical company’s stock worth $5,436,000 after buying an additional 1,254 shares during the period. Legal & General Group Plc increased its position in shares of Intercept Pharmaceuticals by 30.8% during the third quarter. Legal & General Group Plc now owns 8,849 shares of the biopharmaceutical company’s stock worth $1,118,000 after buying an additional 2,086 shares during the period. Vanguard Group Inc. increased its position in shares of Intercept Pharmaceuticals by 2.8% during the third quarter. Vanguard Group Inc. now owns 1,952,931 shares of the biopharmaceutical company’s stock worth $246,772,000 after buying an additional 54,038 shares during the period. Finally, Federated Investors Inc. PA increased its position in shares of Intercept Pharmaceuticals by 1,156.8% during the third quarter. Federated Investors Inc. PA now owns 85,025 shares of the biopharmaceutical company’s stock worth $10,744,000 after buying an additional 78,260 shares during the period. Institutional investors own 68.38% of the company’s stock.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.

Featured Story: Moving Average Convergence Divergence (MACD)

Earnings History and Estimates for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.